右佐匹克隆辅助治疗脑卒中抑郁失眠患者的效果及其对神经认知水平、PSG睡眠指标及血清S100β水平的影响

Effects of eszopiclone on neurocognitive level,PSG sleep index and serum S100β level in patients with stroke,depression and insomnia

目的探究右佐匹克隆辅助治疗脑卒中抑郁失眠患者的效果。方法选取2019年5月至2021年5月河南省直第三人民医院收治的107例脑卒中抑郁失眠患者作为研究对象,根据随机数字表法分为对照组(n=53)和观察组(n=54)。对照组给予单纯舍曲林治疗,观察组在对照组基础上增加右佐匹克隆,对比两组患者神经认知功能、睡眠呼吸监测(PSG)睡眠指标、血清学指标及不良反应发生情况。结果两组不良反应发生率差异无统计学意义(P>0.05);治疗后观察组简易精神状况检查表(MMSE)评分、总睡眠时间(TST)、睡眠效率(SE)、5-羟色胺(5-HT)、脑源性神经营养因子(BDNF)水平高于对照组(P<0.05),神经功能缺损评分(NIHSS)、入睡清醒时间(ATA)、清醒次数(AT)、睡眠潜伏期(SL)、REM潜伏期、S100β水平低于对照组(P<0.05)。结论右佐匹克隆联合舍曲林对脑卒中抑郁失眠患者治疗,可有效改善神经功能和认知功能,提高睡眠质量,安全性高。

【Objective】To explore the effect of eszopiclone in the adjuvant treatment of stroke,depression and insomnia.【Methods】A total of 107 patients with stroke,depression and insomnia in our department were selected and grouped according to random number table.Fifty-three patients in the control group were treated with sertraline alone,and 54 patients in the observation group were treated with eszopiclone.The neurocognitive function,sleep indicators of sleep respiration monitoring(PSG),serological indicators and the occurrence of adverse reactions were compared between the two groups.【Results】There was no statistical significance in the incidence of adverse reactions between the two groups(P>0.05).After treatment,MMSE score,TST,SE,5-HT and BDNF levels in the observation group were higher than those in the control group,while NIHSS score,ATA,AT,SL,REM latency and S 100βlevels were lower than those in the control group(P<0.05).【Conclusion】eszopiclone combined with sertraline in the treatment of stroke patients with depression and insomnia can effectively improve the neurological function and cognitive function,improve sleep quality,with high safety.